(MedPage Today) — Checkpoint blockade with the PD-1 inhibitor balstilimab, alone or in combination with the anti-CTLA-4 drug zalifrelimab, showed activity in women with recurrent or metastatic cervical cancer, preliminary results from two phase…
Read More